Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-01-07 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the progress of using idle funds for cash management, specifically detailing the purchase of financial products with idle funds. It includes detailed information about the amounts, types of products, expected returns, risk management measures, and the impact on the company. The document references a prior shareholders' meeting resolution approving the use of funds for cash management and provides a list of financial products purchased over the past twelve months. The content is focused on updates about financing activities and capital management rather than a full financial report, earnings release, or regulatory certification. It is not a full annual or interim report, nor is it a simple announcement of a report publication. The detailed nature of the cash management and investment activities aligns best with a Capital/Financing Update (CAP).
2019-01-07 Chinese
关于使用部分闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle funds for cash management, specifically detailing purchases of financial products and related risk management measures. It includes specific transaction details, investment amounts, expected yields, and risk mitigation strategies. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or management report. It is a regulatory announcement about capital management activities and investment updates. The document length is about 5888 characters, which is substantial but the content is focused on capital/financing updates rather than financial results or governance. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-01-04 Chinese
关于使用部分闲置自有资金和募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company regarding the use of idle funds and raised capital for cash management, specifically detailing the purchase of financial products such as structured deposits and wealth management products. It includes detailed information on amounts, investment terms, expected yields, and risk management measures. The document references a shareholders' meeting resolution approving the use of funds for cash management and provides a summary of recent transactions and risk controls. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, audit report, or management discussion. The document is a regulatory announcement about financing activities related to cash management and investment of funds. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about financing activities, not just a brief notice or report publication announcement.
2019-01-03 Chinese
独立董事公开征集委托投票权报告书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as an "Independent Director Public Solicitation of Proxy Voting Rights Report" for a 2019 Extraordinary General Meeting (EGM) of shareholders. It details the solicitation process for proxy votes by an independent director, including legal disclaimers, procedures for submitting proxy authorizations, and voting instructions on specific agenda items such as stock option plans and board elections. There are no financial statements, earnings data, or management discussion of financial results. The document is a formal report related to the solicitation of voting rights ahead of a shareholder meeting, not the meeting materials themselves or the voting results. It is not an announcement of a report publication but the report itself. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it concerns proxy solicitation and voting rights related to shareholder meetings. However, since it is specifically about the solicitation of proxy votes by an independent director, it aligns best with the DVA category, which covers official results and voting rights announcements. The document length is under 5,000 characters, but it is a substantive report, not a mere announcement. Therefore, the classification is DVA with high confidence.
2019-01-02 Chinese
2019年股票期权激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation assessment of a 2019 stock option incentive plan by the company. It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, and management of assessment results related to the stock option incentive plan. There is no financial statement, earnings data, or regulatory filing mentioned. The content focuses on governance and management of stock option incentives, which relates to internal governance and management policies rather than financial reporting or regulatory announcements. Therefore, this document fits best under Governance Information (CGR), as it details internal rules and governance practices related to stock option incentive plan assessments.
2019-01-02 Chinese
2019年股票期权激励计划（草案）
Capital/Financing Update Classification · 95% confidence The document is a detailed draft of a 2019 stock option incentive plan for a company, including legal references, plan purpose, management, eligibility, stock option quantities, pricing, conditions, accounting treatment, and implementation procedures. It is a comprehensive plan document outlining the terms and conditions of a stock option incentive scheme, not an announcement or a brief summary. It does not contain financial statements or earnings data, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification. It is not a management or board change announcement. The document is a detailed plan related to capital structure and employee incentives involving stock options, which fits best under Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes through stock option grants.
2019-01-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.